A citation-based method for searching scientific literature

Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare L Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra, Daniela Matei, Anitra Fielding, Stuart Spencer, Brian Dougherty, Maria Orr, Darren Hodgson, J Carl Barrett, Ursula Matulonis. Lancet Oncol 2014
Times Cited: 841



Stan B Kaye, Jan Lubinski, Ursula Matulonis, Joo Ern Ang, Charlie Gourley, Beth Y Karlan, Amit Amnon, Katherine M Bell-McGuinn, Lee-May Chen, Michael Friedlander, Tamar Safra, Ignace Vergote, Mark Wickens, Elizabeth S Lowe, James Carmichael, Bella Kaufman. J Clin Oncol 2012
Times Cited: 323




List of shared articles



Times cited

Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials.
Jiatao Hao, Ying Liu, Taohong Zhang, Jinmei He, Haoyi Zhao, Ruifang An, Yan Xue. Crit Rev Oncol Hematol 2021
2

Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol.
Anita Mansouri, Naomi McGregor, Rachel Dunn, Sam Dobbie, Jane Holmes, Linda Collins, Shibani Nicum. BMJ Open 2021
0

PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival.
Fengping Shao, Yaoyun Duan, Yunhe Zhao, Yinguang Li, Jun Liu, Cai Zhang, Shanyang He. Aging (Albany NY) 2021
1

ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy.
Osnat Elyashiv, Jonathan Ledermann, Gita Parmar, Laura Farrelly, Nicholas Counsell, Amanda Feeney, Fatima El-Khouly, Ian Macdonald, Andreia Neto, Esther Arthur-Darkwa,[...]. Int J Gynecol Cancer 2021
2

Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance.
Dae-Seok Kim, Cristel V Camacho, W Lee Kraus. Exp Mol Med 2021
6

Magnitude of benefit of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for malignant tumor: A meta-analysis.
Lihu Gu, Nannan Du, Qiong Jin, Shengnan Li, Laidi Xie, Jiahang Mo, Zefeng Shen, Danyi Mao, Jia Ji, Parikshit Asutosh Khadaroo,[...]. Crit Rev Oncol Hematol 2020
8


Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial.
Richard T Penson, Ricardo Villalobos Valencia, David Cibula, Nicoletta Colombo, Charles A Leath, Mariusz Bidziński, Jae-Weon Kim, Joo Hyun Nam, Radoslaw Madry, Carlos Hernández,[...]. J Clin Oncol 2020
40

Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review.
Rebecca Arend, Shannon Neville Westin, Robert L Coleman. Int J Gynecol Cancer 2020
2

Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials.
Fengping Shao, Jun Liu, Yaoyun Duan, Li Li, Liqun Liu, Cai Zhang, Shanyang He. Biosci Rep 2020
6